Quality of Life Assessment of Aortic Valve Neocuspidization for Autologous Pericardium: A Systematic Review
Author(s): Komarov RN, Badalyan SS*, Lenkovets M, Tcheglov MI, Magomedova KA and IM Sechenov
Abstract
In 2007, Ozaki et al. conducted the first aortic valve neocuspidation utilizing glutaraldehyde-treated autologous pericardium. Because long-term anticoagulation is not necessary, this procedure has become an option to tissue and mechanical valves. This approach has proven to be a viable alternative to bio prosthetic and mechanical valves, both of which have obvious drawbacks. Digital databases were searched from 2014 to 2022 for the phrases “autologous pericardium”, “aortic valve replacement”, and “aortic valve reconstruction”. Mortality, freedom from surgery, thromboembolic and endocarditis events, and echocardiography findings were all analysed in this study. Non-cardiac causes of death and reoperation were virtually nonexistent. Very few cases of thromboembolic or endocarditis have been reported in this study. A reduced average peak pressure gradient was seen in all investigations following surgery. Autologous pericardium-based aortic valve replacement is both safe and effective. Neocuspidization of the aortic valve offers a less invasive surgical option to biological and mechanical prostheses. Without the requirement for long-term oral anticoagulation, the short- and midterm outcomes are equivalent. Long-term follow-up data is necessary for this new strategy to be broadly implemented.